← Browse by Condition
Medical Condition
marginal zone lymphoma mzl
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 4
NCT07022223 Phase 2
Recruiting
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Enrollment
51 pts
Location
China
Sponsor
Second Affiliated Hospital, Sc...
NCT07208981 Phase 2
Recruiting
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Enrollment
169 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT07355699 Phase 4
Recruiting
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Enrollment
88 pts
Location
China
Sponsor
Beijing Tongren Hospital